EFFICACY AND SAFETY OF TEVERELIX LA, A NEW GNRH ANTAGONIST IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH). RESULTS FROM A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, MULTINATIONAL STUDY INVESTIGATING TWO SINGLE INJECTIONS OF 30 MG OR 60 MG (SEPARATED BY AT LEAST 12 WEEKS) ADMINISTERED SC TO TREATMENT NAIVE PATIENTS SUFFERING FROM BPH